Smartleaf Asset Management’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$16.7K Hold
478
﹤0.01% 2109
2026
Q1
$10.5K Buy
478
+113
+31% +$3.13K ﹤0.01% 2305
2025
Q4
$10.2K Buy
365
+197
+117% +$5.03K ﹤0.01% 2395
2025
Q3
$4.02K Buy
168
+13
+8% +$259 ﹤0.01% 2446
2025
Q2
$2.6K Sell
155
-69
-31% -$1.2K ﹤0.01% 2257
2025
Q1
$4.97K Sell
224
-122
-35% -$3.2K ﹤0.01% 2188
2024
Q4
$8.74K Buy
346
+216
+166% +$5.51K ﹤0.01% 2043
2024
Q3
$3.26K Buy
130
+22
+20% +$568 ﹤0.01% 2305
2024
Q2
$2.59K Buy
108
+93
+620% +$2.28K ﹤0.01% 2117
2024
Q1
$509 Buy
+15
New +$467 ﹤0.01% 1738

Other funds holding BEAM

Smartleaf Asset Management's BEAM Position: Q2 2026 in Review

Smartleaf Asset Management held its Beam Therapeutics (BEAM) position steady in Q2 2026 at 478 shares worth $16.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2109.

Smartleaf Asset Management first reported a position in BEAM in Q1 2024 and has held it in 10 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Smartleaf Asset Management held 478 shares of Beam Therapeutics worth $16.7K as of Q2 2026.
  • Smartleaf Asset Management left its Beam Therapeutics share count unchanged in Q2 2026.
  • Beam Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #2109 holding.
  • Smartleaf Asset Management first reported a position in Beam Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.